BGMA Hits Back At ABPI Complaints Over UK Pricing Scheme

VPAG Is ‘Delivering Precisely As Intended’, Says Generics Chief

Complaints from UK originator association the ABPI over rising payments required by the country’s voluntary scheme for branded medicines pricing have been denounced by the BGMA, which says the differentiated scheme is “delivering precisely as it was intended.”

The BGMA has responded to counter the ABPI’s messaging over VPAG (Shutterstock)

More from Regulation

More from Biosimilars